



**Amendments to the claims:**

1. (original) A pharmaceutical composition for treatment of pain, which comprises in combination a benzothiadiazole derivative of formula I




wherein each R1, R2 and R3 independently, is hydrogen, halogen, C<sub>1</sub>-C<sub>7</sub> alkyl, C<sub>1</sub>-C<sub>7</sub> alkoxy, nitro, cyano, hydroxy or C<sub>1</sub>-C<sub>7</sub> alkylthio;  
and a COX-2 inhibitor for simultaneous, sequential or separate use.

2. (canceled)
3. (canceled)
4. (currently amended) A method of treating a patient suffering from pain comprising administering to the patient an effective amount of a benzothiadiazole derivative of formula I as defined above,




wherein each R1, R2 and R3 independently, is hydrogen, halogen, C<sub>1</sub>-C<sub>7</sub> alkyl, C<sub>1</sub>-C<sub>7</sub> alkoxy, nitro, cyano, hydroxy or C<sub>1</sub>-C<sub>7</sub> alkylthio,  
and an effective amount of a COX-2 inhibitor.

5. (currently amended) A package comprising a benzothiadiazole derivative of formula I ~~as defined in claim 1,~~



wherein each R1, R2 and R3 independently, is hydrogen, halogen, C<sub>1</sub>-C<sub>7</sub> alkyl, C<sub>1</sub>-C<sub>7</sub> alkoxy, nitro, cyano, hydroxy or C<sub>1</sub>-C<sub>7</sub> alkylthio, for treatment of pain according to a method wherein said benzothiadiazole derivative of formula I is used together ~~with instructions for use~~ in combination with a COX-2 inhibitor for treatment of pain, or a package comprising a COX-2 inhibitor for treatment of pain according to a method wherein said COX-2 inhibitor is used ~~together with instructions for use~~ in combination with a benzothiadiazole derivative of formula I as defined above in ~~claim 1,~~ for treatment of pain.

6. (currently amended) A composition ~~method, use or package~~ according to claim 1 ~~any one of the preceding claims~~ in which the COX-2 inhibitor is selected from the group consisting of rofecoxib, etoricoxib, celecoxib, valdecoxib, parecoxib, ~~or~~ and a 5-alkyl-2-arylaminophenylacetic acid derivative COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, or any hydrate thereof.
7. (currently amended) A composition ~~method, use or package~~ according to claim 1 ~~[[7]]~~ in which the COX-2 inhibitor is a compound of formula V



wherein R is methyl or ethyl;

R<sub>1</sub> is chloro or fluoro;

R<sub>2</sub> is hydrogen or fluoro;

R<sub>3</sub> is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy;

R<sub>4</sub> is hydrogen or fluoro; and

R<sub>5</sub> is chloro, fluoro, trifluoromethyl or methyl,

or a pharmaceutically acceptable salt or ester thereof.

8. (currently amended) A composition ~~method, use or package~~ according to claim 7 in which the COX-2 inhibitor is 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid,  
or a pharmaceutically acceptable salt or ester thereof.
9. (currently amended) A composition ~~method, use or package~~ according to claim 1 ~~any one of the preceding claims~~ in which the benzothiadiazole derivative is 5-chloro-4-(2-imidazol-2-ylamino)-2,1,3-benzothiadiazole.